Last reviewed · How we verify
Placebo of Levosimendan
This is a placebo control arm and contains no active drug; it serves as a comparator in clinical trials of levosimendan.
This is a placebo control arm and contains no active drug; it serves as a comparator in clinical trials of levosimendan. Used for Placebo control in phase 3 trials of levosimendan for acute decompensated heart failure.
At a glance
| Generic name | Placebo of Levosimendan |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
As a placebo, this formulation is pharmacologically inert and is used in phase 3 trials to establish the efficacy and safety of the active levosimendan drug through blinded comparison. Levosimendan itself is a calcium sensitizer and vasodilator used in acute heart failure, but the placebo arm has no mechanistic activity.
Approved indications
- Placebo control in phase 3 trials of levosimendan for acute decompensated heart failure
Common side effects
Key clinical trials
- LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 (PHASE3)
- LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF (PHASE3)
- Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS (PHASE3)
- Shorter Weaning From Invasive Ventilation With Levosimendan (PHASE4)
- Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage (PHASE2)
- Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock (PHASE3)
- Levosimendan In Ambulatory Heart Failure Patients (PHASE4)
- Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of Levosimendan CI brief — competitive landscape report
- Placebo of Levosimendan updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI